Eli Lilly | LLY - Net Income


Eli Lilly reported $7.1B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Abbott USD 920M 8M Sep/2026
ALKERMES USD 501K 66.98M Jun/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Baxter International USD 294M 168M Sep/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Drreddys Laboratories INR 2.21B 9.89B Mar/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
J&J USD 210M 5.32B Sep/2026
Medtronic USD 1.47B 227M Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Novartis USD 3.16B 747M Mar/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Perrigo USD 74.5M 473.1M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Phibro Animal Health USD 27.46M 932K Dec/2025
Prestige Brands USD 38.54M 15.39M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Sanofi EUR 1.61B 2.42B Mar/2026
United Therapeutics USD 333M 58.1M Jun/2026
Zoetis USD 691M 90M Jun/2026